Tuesday, November 10, 2026

BTC $72,867 ▼ 2.67%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

BTC$72,867−2.67%ETH$2,016−5.26%SOL$81.90−5.76%XRP$1.05−4.83%LINK$10.15−4.91%ADA$0.172−4.35%S&P 5007,491−0.77%Nasdaq24,938−1.25%Dow52,095−0.56%RUT2,804−1.29%TNX5.01%+3.06%TYX5.37%+2.21%FVX4.84%+3.91%IRX4.13%+2.23%VIX20.82+4.52%GOLD$4,030.20−2.05%SILVER$51.29−2.67%OIL$86.71−0.16%DXY102.35+0.69%NVDA$166.92−6.58%AAPL$348.24−0.70%TSLA$375.71−0.62%META$640.39−0.15%MSFT$542.86−0.43%AMZN$268.82+0.71%GOOGL$287.23−0.32%Fear & Greed32 — FearBTC$72,867−2.67%ETH$2,016−5.26%SOL$81.90−5.76%XRP$1.05−4.83%LINK$10.15−4.91%ADA$0.172−4.35%S&P 5007,491−0.77%Nasdaq24,938−1.25%Dow52,095−0.56%RUT2,804−1.29%TNX5.01%+3.06%TYX5.37%+2.21%FVX4.84%+3.91%IRX4.13%+2.23%VIX20.82+4.52%GOLD$4,030.20−2.05%SILVER$51.29−2.67%OIL$86.71−0.16%DXY102.35+0.69%NVDA$166.92−6.58%AAPL$348.24−0.70%TSLA$375.71−0.62%META$640.39−0.15%MSFT$542.86−0.43%AMZN$268.82+0.71%GOOGL$287.23−0.32%Fear & Greed32 — Fear

Tag

mrna

4 articles

Moderna Crushes Q3 Estimates, Narrows Spending Outlook

U.S. Equities4d ago

Moderna Crushes Q3 Estimates, Narrows Spending Outlook

The biotech reported $1.31B in revenue and 38-cent EPS, both crushing consensus, while guiding FY capital spending to $200M and R&D to $2.7B.

Moderna at $225: Melanoma Data and NIH Backing Justify Bull Case

U.S. Equities29d ago

Moderna at $225: Melanoma Data and NIH Backing Justify Bull Case

Moderna has surged 600 percent in 2026 on melanoma vaccine efficacy and reported NIH support for personalized cancer vaccines, with analysts modeling $225 as fair value.

Moderna Surges 177% on Melanoma Vaccine Win; Wall Street Raises Targets

U.S. Equities79d ago

Moderna Surges 177% on Melanoma Vaccine Win; Wall Street Raises Targets

Moderna stock soared on positive Phase 3 results for its personalized melanoma vaccine with Merck, prompting Morgan Stanley to raise its price target to $89 from $39.

Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk

U.S. Equities80d ago

Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk

Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.